Lung cancer has been a significant socioeconomic problem over the past 10 years, occupying leading positions in the structure of cancer deaths. Surgery remains the main treatment for localized lung cancer. The high rate of postoperative complications (up to 30%) and deaths of up to 9% are an unresolved problem.

OBJECTIVE

To reduce the rate of postoperative complications in patients with lung cancer during lymphotropic drug use in the perioperative period.

SUBJECTS AND METHODS

The investigation enrolled 124 patients with non-small cell lung cancer who were evenly divided according to additional parameters into 3 groups in relation to the postoperative therapy performed: 1) 50 patients who received standard postoperative therapy; 2) 44 patients in whom standard therapy was performed in combination with lymphotropic therapy according to the procedure developed by Professor A.A. Zeydlits; 3) 30 patients who used standard therapy in combination with lymphotropic therapy according to the authors’ proposed procedure. The efficiency of the latter was evaluated with single-photon emission computed tomography (SPECT) using Technefit; blood cortisol levels were measured in the perioperative period; VAS scores were calculated; all recorded complications were stratified by the Thoracic Morbidity and Mortality (TMM) System.

RESULTS

Compared with standard treatment, lymphotropic therapy showed a 1.8-fold decrease in pain intensity. There was also a reduction in the rate of severe postoperative complications (Grade IIIA, IIIB to 3.3% and the absence of IVA, Grade V) compared to the control group (the rates of Grade IIIA, IIIB, IVA, Grade V (mortality) were 10, 20, 4 and 4%, respectively).

CONCLUSION

The developed lymphotropic therapy procedure can reduce pain intensity in the postoperative period and also ensures a decrease in the rate of pyoinflammatory complications in the examinees.